Diligence memo · auto-generated · as of July 2, 2026
Surterra Holdings, Inc./DE
Surterra Holdings, Inc./DE looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Surterra Holdings, Inc./DE operates in Pharmaceuticals, based in ATLANTA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Surterra Holdings, Inc./DE has raised $230M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $165M on 2018-10-16.
Most recent recorded round closed around 2018-10-16.
Valuation (modeled)modeled
Provath models Surterra Holdings, Inc./DE at approximately $5.8B (range $787M–$12.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.32× the median modeled value of Series D+ Pharmaceuticals companies in 2016–2018 (11 peers) — value vs value, same stage and era. Within the normal band (132% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 1 months.
Last raise 7.7 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 3.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 97% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: Concordia International Corp., Ironwood Pharmaceuticals Inc, Melinta Therapeutics, Inc. /New/, Beam Therapeutics Inc., Tris Pharma, Inc..
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.